| Literature DB >> 24621868 |
Divya Gupta1, Vasiliki V Georgiopoulou1, Andreas P Kalogeropoulos1, Catherine N Marti1, Clyde W Yancy2, Mihai Gheorghiade2, Gregg C Fonarow3, Marvin A Konstam4, Javed Butler5.
Abstract
Combination therapy with hydralazine and nitrates can improve outcomes in patients with heart failure and low ejection fraction. However, this combination is underused in clinical practice for several reasons, including side effects related to hydralazine and polypharmacy. Some of the benefits seen with hydralazine, including afterload reduction and attenuation of nitrate tolerance, have also been observed with angiotensin-converting enzyme inhibitors. Demonstrating similar clinical benefits with nitrates plus angiotensin-converting enzyme inhibitor therapy alone, in the absence of hydralazine, may represent an opportunity to improve heart failure care by increasing the use of nitrates. In this paper, we summarize data that support studying such an approach.Entities:
Keywords: heart failure; hydralazine; nitrate; pseudotolerance; renin angiotensin aldosterone system; tolerance
Mesh：
Substances：
Year: 2013 PMID： 24621868 DOI： 10.1016/j.jchf.2013.03.003
Source DB: PubMed Journal: JACC Heart Fail ISSN： 2213-1779 Impact factor: 12.035